Nanexa signs €1.165B global licensing deal with Novo

Nanexa and Novo announced a global exclusive licensing and collaboration agreement valued up to €1.165B, marking a major commercial validation of Nanexa's drug delivery platform. Financial terms and milestone structure remain undisclosed, and the deal's impact on Novo's pipeline is uncertain. This is a significant corporate development for both firms, likely to move Nanexa's share price and signal confidence in its technology.